Trial Profile
Electrophysiological Biomarkers of Kynurenine Pathway Modulator AV-101 in Healthy Volunteers: Treating Suicidal Veterans
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs AV 101 (Primary)
- Indications Major depressive disorder; Neuropathic pain; Psychiatric disorders; Suicidal ideation
- Focus Biomarker; Therapeutic Use
- 19 Dec 2019 According to a VistaGen Therapeutics media release, VistaGen and the U.S. Department of Veterans Affairs (VA) entered into a Material Transfer Cooperative Research and Development Agreement (MT CRADA) regarding clinical trial material for this study, and VA funding was provided for all other study costs.
- 19 Dec 2019 According to a VistaGen Therapeutics media release, Michael E. DeBakey VA Medical Center (MEDVAMC) in Houston served as Principal Investigator of the study.
- 19 Dec 2019 Results presented in a VistaGen Therapeutics Media Release.